Generate Biomedicines, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Quarterly earnings show how the company is performing and whether it's growing or losing money.
The 10-Q provides detailed financial statements and updates about the company's business activities.
The 10-Q provides detailed financial statements and updates about the company's business activities.
Quarterly earnings show how the company is performing and whether it's growing or losing money.
Going public means the company is now owned by regular investors and must report its finances publicly.
The IPO raises money for the company to fund research and operations, and creates public shareholders.
The S-1 is the official document the SEC reviews before allowing a company to go public.
Stocky reads Generate Biomedicines, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Generate Biomedicines, Inc.'s most recent tracked filing was a 8-K on 6 Aug 2026: Reports Q2 2026 financial results on August 6.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.